| Item | Description | Owner | Notes | Action |
|---|
| 1 | Call to order and role call | JCA | | |
| 2 | Approval of 20160627 minutes | JCA | | - Approve minutes from 06/27/2016
|
| 3 | | | | Drug model content | JCA | Decision from Copenhagen 2015, that the prescribing use case is not going to be supported. Thus the need for universal restrictions in the DL is not needed at this time. Questions regarding the names of drug products that contain SOME substances if we disallow the use of universal restrictions: - Which concepts have this potential problem? - How to construct the FSN to make it unambiguous? - If we change the FSN, is it a technical correction or retire and replace? | |
| 4 | Assessment instrument responses | JCA | Policy on addition of assessment tool responses to the International edition. IHTSDO currently accepts "names" of assessment instruments and staging scales; however, there is nothing in the editorial guide that specifically addresses the responses to assessment instrument questions. As many of these are extremely context dependent, being tied specifically to the particular instrument, what should be the policy of IHTSDO to requests to add assessment instrument responses to the International release. Example: Requests to add responses to Tinetti balance assessment tool | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | Action item review | EAG | Space Actions | |
| 10 | Potential agenda topics for Wellington meeting | JCA | We are meeting for a full day in New Zealand. Need substantive topics to move forward. AG Member travel FAQ: https://ihtsdo.freshdesk.com/support/solutions/folders/4000008052 | - Solicit additional agenda topics for Face-to-face meeting
- Verify travel requests have been submitted
|
| 11 | September conference call date and time verification | JCA | JCA is traveling Sept 10-23. Meeting scheduled for Sept 26 | |
| 12 | Additional items | EAG | Informational item: In order to support the use of qualifier values for nominal results reporting in laboratory and other clinical domains, the range of values allowed for the HAS INTERPRETATION relationship will be extended beyond << 260245000 | Findings values (qualifier value) |. The initial extension will be < 263714004 | Colors (qualifier value) |. Additional subhierarchies will be added as necessary to support specific international use cases submitted by members. | |